Frailty and P2Y12 Inhibitors: Does The Best Approach Need to Be Black or White?

We have read with interest the manuscript by Ko et al1 about frailty and P2Y12 inhibitors. As the authors state, the choice of the most adequate antiplatelet therapy is key, and it is 1 of the most challenging issues in the care of this subgroup of patients. In their series, the 2 major players limiting the use of prasugrel and ticagrelor were anemia and frailty, but despite these factors, the use of clopidogrel was reduced from 78.3% in the period 2010 to 2013 to 42.1% in the interval 2018 to 2020.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Tags: Readers ’ Comments Source Type: research